Gut microbiome profiles associated with steatosis severity in metabolic associated fatty liver disease

Abstract

Aim: The microbiome has been shown to be pivotal in the development of metabolic associated fatty liver disease (MAFLD). Few have examined the relationship of the microbiome specifically with steatosis grade. Therefore, our aim was to characterize the association of the microbiome with MAFLD steatosis severity while adjusting for metabolic comorbidities including diabetes.

Methods: We enrolled patients with MAFLD at the West Los Angeles Veterans Affair Hospital. All patients underwent ultrasound elastography, fasting serum collection, and fecal sampling for 16S sequencing. We examined the associations of microbial diversity and composition with advanced steatosis, defined as a CAP score of ≥ 300 dB/m, with or without the presence of metabolic comorbidities.

Results: Seventy-five patients were enrolled. African American were less likely to have advanced steatosis than either Hispanics or Whites (P = 0.001). Patients with more advanced steatosis had higher fasting serum triglyceride (192.6 ± 157.1 mg/dL vs. 122.5 ± 57.4 mg/dL), HbA1c (6.7% ± 1.4% vs. 6.1% ± 0.8%), transaminases, and were more likely to have metabolic syndrome (52.4% vs. 24.2%, P = 0.02). Advanced steatosis and diabetes were associated with altered microbial composition. Bacteroides was negatively associated with advanced steatosis while Megasphaera was positively associated with steatosis. Akkermansia was negatively associated with diabetes, while Anaerostipes and Parabacteroides were positively associated with diabetes.

Conclusion: Diabetes and metabolic syndrome are associated with hepatic steatosis severity in MAFLD patients and both advanced steatosis and comorbid diabetes are independently associated with microbiome changes. These results provide insight into the role of the gut microbiome in MAFLD associated with metabolic syndrome.

Keywords

Metabolic syndrome / nonalcoholic fatty liver disease / microbiome / obesity / ultrasound elastography / advanced steatosis / diabetes

References

[1] Stewart ST,Rosen AB.Forecasting the effects of obesity and smoking on U.S. life expectancy.N Engl J Med2009;361:2252-60 PMCID:PMC4394736

[2] Nelson KM.The burden of obesity among a national probability sample of veterans.J Gen Intern Med2006;21:915-9 PMCID:PMC1831589

[3] Younossi ZM,Afendy M.Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.Clin Gastroenterol Hepatol2011;9:524-530.e1; quiz e60

[4] Goldberg D,Saeian K.Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation.Gastroenterology2017;152:1090-9.e1 PMCID:PMC5367965

[5] Sjöström L,Jacobson P.Bariatric surgery and long-term cardiovascular events.JAMA2012;307:56-65

[6] Shreiner AB,Young VB.The gut microbiome in health and in disease.Curr Opin Gastroenterol2015;31:69-75 PMCID:PMC4290017

[7] Zhu L,Gill C.Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH.Hepatology2013;57:601-9

[8] Louis S,Damms-Machado A,Bischoff SC.Characterization of the gut microbial community of obese patients following a weight-loss intervention using whole metagenome shotgun sequencing.PLoS One2016;11:e0149564 PMCID:PMC4769288

[9] Bajaj JS,Ridlon JM.Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation.Am J Physiol Gastrointest Liver Physiol2012;303:G675-85 PMCID:PMC3468538

[10] Turnbaugh PJ,Yatsunenko T.A core gut microbiome in obese and lean twins.Nature2009;457:480-4 PMCID:PMC2677729

[11] Dong TS,Lagishetty V.A microbial signature identifies advanced fibrosis in patients with chronic liver disease mainly due to NAFLD.Sci Rep2020;10:2771 PMCID:PMC7026172

[12] Million M,Yahav D.Gut bacterial microbiota and obesity.Clin Microbiol Infect2013;19:305-13

[13] Turnbaugh PJ,Faith JJ,Knight R.The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice.Sci Transl Med2009;1:6ra14 PMCID:PMC2894525

[14] Dong TS.Nonalcoholic fatty liver disease and the gut microbiome: are bacteria responsible for fatty liver?.Exp Biol Med (Maywood)2019;244:408-18 PMCID:PMC6547005

[15] Jun BG,Park EJ.A prospective comparative assessment of the accuracy of the FibroScan in evaluating liver steatosis.PLoS One2017;12:e0182784 PMCID:PMC5557594

[16] Grundy SM,Daniels SR.American Heart AssociationNational HeartLungand Blood InstituteDiagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.Circulation2005;112:2735-52

[17] Dong TS,Lagishetty V.A high protein calorie restriction diet alters the gut microbiome in obesity.Nutrients2020;12:3221 PMCID:PMC7590138

[18] Martino C,Marotz CA.A novel sparse compositional technique reveals microbial perturbations.mSystems2019;4:e00016-19 PMCID:PMC6372836

[19] Love MI,Anders S.Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.Genome Biol2014;15:550 PMCID:PMC4302049

[20] Adams LA,Knuiman MW,Olynyk JK.NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study.Am J Gastroenterol2009;104:861-7

[21] Rosselli M,Vizzutti F,Pinzani M.The metabolic syndrome and chronic liver disease.Curr Pharm Des2014;20:5010-24

[22] Rich NE,Mufti AR.Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis.Clin Gastroenterol Hepatol2018;16:198-210.e2 PMCID:PMC5794571

[23] Loomba R,Li W.Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease.Cell Metab2017;25:1054-62.e5 PMCID:PMC5502730

[24] Qiao S,Wang K.Activation of a specific gut bacteroides-folate-liver axis benefits for the alleviation of nonalcoholic hepatic steatosis.Cell Rep2020;32:108005

[25] Caussy C,Humphrey G.A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease.Nat Commun2019;10:1406 PMCID:PMC6440960

[26] Qingxi-Zhao, Hongyun-Wei. Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis.Ann Hepatol2019;18:796-803

[27] Bashiardes S,Rozin S,Elinav E.Non-alcoholic fatty liver and the gut microbiota.Mol Metab2016;5:782-94 PMCID:PMC5004228

[28] Buzzetti E,Tsochatzis EA.The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).Metabolism2016;65:1038-48

[29] Caussy C,Lo MT.Genetics of NAFLD in Twins ConsortiumLink between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD.Hepatology2018;68:918-32 PMCID:PMC6151296

[30] Da Silva HE,Comelli EM.Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance.Sci Rep2018;8:1466 PMCID:PMC5780381

[31] Dao MC,Aron-Wisnewsky J.MICRO-Obes ConsortiumAkkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology.Gut2016;65:426-36

[32] Depommier C,Druart C.Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study.Nat Med2019;25:1096-103 PMCID:PMC6699990

[33] Everard A,Geurts L.Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity.Proc Natl Acad Sci U S A2013;110:9066-71 PMCID:PMC3670398

[34] Plovier H,Druart C.A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice.Nat Med2017;23:107-13

[35] Dedrick S,Huang Q.The role of gut microbiota and environmental factors in type 1 diabetes pathogenesis.Front Endocrinol (Lausanne)2020;11:78 PMCID:PMC7057241

[36] Hasain Z,Kamaruddin NA.Gut microbiota and gestational diabetes mellitus: a review of host-gut microbiota interactions and their therapeutic potential.Front Cell Infect Microbiol2020;10:188 PMCID:PMC7243459

[37] Das SR,Yancy WS Jr.Obesity prevalence among veterans at Veterans Affairs medical facilities.Am J Prev Med2005;28:291-4

[38] Bauer PV,Waise TMZ.Metformin alters upper small intestinal microbiota that impact a Glucose-SGLT1-Sensing glucoregulatory pathway.Cell Metab2018;27:101-117.e5

[39] Dong TS,Hauer M.Metformin alters the duodenal microbiome and decreases the incidence of pancreatic ductal adenocarcinoma promoted by diet-induced obesity.Am J Physiol Gastrointest Liver Physiol2019;317:G763-72 PMCID:PMC6962494